Should You Hold Bio-Techne Corp. (TECH) For the Long Term?
Conestoga Capital Advisors, an asset management company, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Bio-Techne Corp (TECH)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Royce & Associates Chuck Royce | 870,185 | $51,018,947 | +2% | 0.55% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $352.55 | 300 | 10,106 | 2022-05-10 | Filing | ||
| $185.00 | 100 | Officer, Director | 100 | 2019-09-09 | Filing | |
| $185.00 | 100 | Officer, Director | 100 | 2019-09-09 | Filing | |
| $191.06 | 500 | Director | 8,726 | 2019-08-07 | Filing | |
| $65.00 | 2,361 | Director | 70,000 | 2013-05-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $65.96 | 1,860 | Director | 1,976 | 2025-02-14 | Filing | |
| $77.95 | 1,661 | Officer, Director | 39,004 | 2025-01-27 | Filing | |
| $77.19 | 11,731 | Officer, Director | 40,665 | 2025-01-27 | Filing | |
| $72.10 | 16,000 | Director | 43,401 | 2024-08-08 | Filing | |
| $83.84 | 4,000 | Director | 36,608 | 2024-05-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,746,351 | $805,948,514 | 0.02% | |
| 2. | 3,025,409 | $177,379,730 | 0.06% | |
| 3. | 2,414,371 | $141,554,554 | 0.03% | |
| 4. | 2,030,535 | $119,050,267 | 0.08% | |
| 5. | 1,912,377 | $112,122,666 | 0.16% |
News See All
Bio-Techne Corporation (TECH) Slid Due to NIH’s Funding Concerns
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Weitz Partners III Opportunity Fund Added Bio-Techne Corporation (TECH) to its Portfolio
Weitz Investment Management, an investment management firm, released its “Partners III Opportunity Fund” fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Bio-Techne Corporation (NASDAQ:TECH) Q2 2025 Earnings Call Transcript
Operator: Good morning. And welcome to the Bio-Techne earnings conference call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode.
Bio-Techne Corporation (NASDAQ:TECH) Q1 2025 Earnings Call Transcript
Operator: Good morning, and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year 2025.
Here’s What Dragged Bio-Techne Corporation (TECH)?
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” second quarter 2024 investor letter.
Bio-Techne Corporation (NASDAQ:TECH) Q4 2024 Earnings Call Transcript
Operator: [Call Starts Abruptly] Call for the Fourth Quarter of Fiscal Year 2024.
Multiple Headwinds Dragged Bio-Techne Corp. (TECH) in Q1
Conestoga Capital Advisors, an asset management company, released its “Mid-Cap Strategy” first-quarter 2024 investor letter. A copy of the letter can be downloaded here.
Bio-Techne Corporation (TECH) Declined on Weak Q4 Results
Baron Funds, an investment management company, released its “Baron Asset Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Billionaire Hedge Funds
